XRAY · DENTSPLY SIRONA Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| R&D as a percentage of net sales | 5% | Three Months Ended June 30, 2026 filing | — |
| Segment adjusted operating income non-GAAP | $201M | Three Months Ended June 30, 2026 filing | — |
| SG&A as a percentage of net sales | 40.6% | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XRAY
this stock
DENTSPLY SIRONA Inc.
|
$1.72B | -26.3% | -3.0% | — | 12.8% |
|
ISRG
Intuitive Surgical Inc
|
$153.03B | -23.5% | +20.5% | 49.7 | 2.1% |
|
BDX
Becton Dickinson & Co
|
$52.22B | — | +8.2% | — | 3.6% |
|
MDLN
Medline Inc.
|
$46.26B | -16.2% | +11.5% | — | 4.0% |
|
RMD
Resmed Inc
|
$34.59B | -0.5% | +13.4% | 23.0 | 8.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XRAY | -1.3% | -10.8% | -28.5% | -5.0% | -26.3% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +0.2% | -9.9% | -36.2% | -5.5% | -38.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.